High-Level Overview
Walking Fish Therapeutics was a biotechnology company that engineered B cells as protein factories to develop cell-based therapeutics for serious diseases, including cancer, autoimmune disorders, rare diseases like Fabry disease, and applications in regenerative medicine and infectious diseases.[1][2][3] Based in South San Francisco, California, it targeted oncology, solid tumors, and unmet needs in immuno-oncology by leveraging B cell biology for targeted antibody and protein production, serving patients with cancers, autoimmune conditions, and deficiencies.[1][2][3] The company raised $73 million across two Series A rounds ($50M in September 2021 and $23M in February 2022) but ceased operations in May 2024 after a lead investor withdrew from a planned Series B, just before seeking clinical trial clearance for its Fabry disease program.[1]
Origin Story
Walking Fish Therapeutics was founded in 2019 (with some sources noting 2018) by a team of alumni from Five Prime Therapeutics, led by CEO Rusty Williams, MD, PhD, who brought expertise in protein therapeutics and immuno-oncology.[1][2][4] The idea emerged from advances in B cell engineering, inspired by the regenerative abilities of the axolotl, aiming to create B cells as long-lived, potent factories for antibodies and proteins to address cancers, autoimmune diseases, and regenerative needs.[3] Early traction included an oversubscribed $50M Series A in 2021, expansion of its leadership team with COO Georgia Erbez, and a move to a 22,000-square-foot headquarters and lab in South San Francisco as it advanced programs like WFT-1 toward clinical trials.[1][2]
Core Differentiators
- B Cell Engineering Platform: Developed a broad platform reprogramming B cells into targeted protein and antibody factories, with deep expertise in B cell biology for selective, local responses in tissues, outperforming traditional therapies in oncology and rare diseases.[1][2][3]
- Pipeline Focus: Preclinical assets included WFX-001 (GALA stimulant for Fabry disease), WFX-002 and WFX-003 (cell replacements for solid tumors and regenerative medicine), and WFT-2/WFT-3 for solid tumors and rare diseases, emphasizing antitumor immune responses and muscle-preserving treatments.[1][3][5]
- Therapeutic Versatility: Addressed oncology, autoimmune, regenerative medicine, and infectious diseases with engineered CAR-B cells for precise delivery, positioning it as a leader in a novel cell therapy modality beyond T cells.[1][2][3]
- Operational Momentum: Built a world-class lab, expanded team, and generated candidates across multiple fields before shutdown, demonstrating rapid progress from founding to near-clinical stage.[2]
Role in the Broader Tech Landscape
Walking Fish rode the wave of next-generation cell therapies, shifting from T cell-focused CAR-T to B cell engineering for durable, off-the-shelf protein production amid rising demand for immuno-oncology and regenerative solutions post-2020 biotech boom.[1][3] Timing aligned with investor enthusiasm for platform technologies, as seen in its $73M raise, but highlighted biotech volatility—market forces like high interest rates and investor pullbacks in 2023-2024 led to its demise despite preclinical promise.[1] It influenced the ecosystem by validating B cells as a viable modality, paving the way for competitors like Immusoft in muscle-preserving therapies and advancing discourse on tissue-specific immune responses for unmet needs in solid tumors and rare diseases.[1][3]
Quick Take & Future Outlook
With operations ending in May 2024, Walking Fish's assets, including its Fabry program and lab equipment, were auctioned, marking the end of its journey but underscoring B cell platforms' potential in biotech.[1] Trends like AI-driven protein design and combination immunotherapies will shape successors, potentially reviving its IP through acquisitions amid ongoing demand for novel cell factories. Its influence endures as a cautionary tale of funding risks, yet a proof-of-concept for B cell innovation that could evolve through larger players, tying back to its ambitious vision of axolotl-inspired regeneration for intractable diseases.[1][3]
